Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Clin Kidney J
2012 Jun 01;53:195-202. doi: 10.1093/ckj/sfs029.
Show Gene links
Show Anatomy links
Aquaporin-2: new mutations responsible for autosomal-recessive nephrogenic diabetes insipidus-update and epidemiology.
Bichet DG
,
El Tarazi A
,
Matar J
,
Lussier Y
,
Arthus MF
,
Lonergan M
,
Bockenhauer D
,
Bissonnette P
.
???displayArticle.abstract???
It is clinically useful to distinguish between two types of hereditary nephrogenic diabetes insipidus (NDI): a 'pure' type characterized by loss of water only and a complex type characterized by loss of water and ions. Patients with congenital NDI bearing mutations in the vasopressin 2 receptor gene, AVPR2, or in the aquaporin-2 gene, AQP2, have a pure NDI phenotype with loss of water but normal conservation of sodium, potassium, chloride and calcium. Patients with hereditary hypokalemic salt-losing tubulopathies have a complex phenotype with loss of water and ions. They have polyhydramnios, hypercalciuria and hypo- or isosthenuria and were found to bear KCNJ1 (ROMK) and SLC12A1 (NKCC2) mutations. Patients with polyhydramnios, profound polyuria, hyponatremia, hypochloremia, metabolic alkalosis and sensorineural deafness were found to bear BSND mutations. These clinical phenotypes demonstrate the critical importance of the proteins ROMK, NKCC2 and Barttin to transfer NaCl in the medullary interstitium and thereby to generate, together with urea, a hypertonic milieu. This editorial describes two new developments: (i) the genomic information provided by the sequencing of the AQP2 gene is key to the routine care of these patients, and, as in other genetic diseases, reduces health costs and provides psychological benefits to patients and families and (ii) the expression of AQP2 mutants in Xenopus oocytes and in polarized renal tubular cells recapitulates the clinical phenotypes and reveals a continuum from severe loss of function with urinary osmolalities <150 mOsm/kg H2O to milder defects with urine osmolalities >200 mOsm/kg H2O.
Fig. 1. (a) Immunofluorescence of AQP2 expressed in oocytes. Oocytes were not injected (1 control) or injected with either AQP2-wt (2, 1 ng), AQP2-D150E (3, 10 ng) or AQP2-G196D (4, 10 ng) messenger RNAs and incubated for 3 days prior to assay. Oocytes were immunostained and visualized with antibodies to AQP2. The injection process is represented in the right of the figure [21]. (b) Determination of water permeabilities (Pf) of wild-type (WT) AQP2 and mutants expressed in Xenopus oocytes. Oocytes were injected with either AQP2-wt (1 ng), AQP2-D150E (10 ng) or AQP2-G196D (10 ng) messenger RNAs and incubated for 2 days prior to assay. Determination of water permeabilities was performed by evaluation of volume increase in oocytes as induced by a 20-mosmol/kg H2O hypotonic shock [21].
Fig. 2. Pedigree of three Pakistani families referred to our laboratory each bearing the V71M AQP2 mutation (M). Family Aqp1 was first described by Langley [16]. Squares and circles represent male and female subjects, respectively, with unaffected individuals (open symbols), carriers (half-filled symbols) and affected individuals (solid symbol); n indicates normal allele. Haplotypes consist of markers that flank the AQP2 gene and that have been described previously [24]. The alleles bearing the individual mutations are identical suggesting a common ancestry.
Fig. 3. A representation of the AQP2 protein and identification of 46 putative disease-causing AQP2 mutations. A monomer is represented with six transmembrane helices. The location of the PKA phosphorylation site (Pa) is indicated. The extracellular, transmembrane and cytoplasmic domains are defined according to Deen et al. [17]. Solid symbols indicate the location of the mutations (for references, view Table 1): M1I; L22V; V24A; L28P; G29S; A47V; Q57P; G64R; N68S; A70D; V71M; R85X; G100X; G100V; G100R; I107D; 369delC; T125M; T126M; A147T; D150E; V168M; G175R; G180S; C181W; P185A; R187C; R187H; A190T; G196D; W202C; G215C; S216P; S216F; K228E; R254Q; R254L; E258K and P262L. GenBank accession numbersâAQP2: AF147092, Exon 1; AF147093, Exons 2 through 4. NPA motifs and the N-glycosylation site are also indicated.
Fig. 4. A young patient's thirsty since birth.
Fig. 5. Schematic representation of the effect of vasopressin (AVP) to increase water permeability in the principal cells of the collecting duct. AVP is bound to the V2 receptor (a G-protein-linked receptor) on the basolateral membrane. The basic process of G-protein-coupled receptor signaling consists of three steps: a hepta-helical receptor that detects a ligand (in this case, AVP) in the extracellular milieu, a G-protein (Gα
s) that dissociates into a subunits bound to guanosine triphosphate and bg subunits after interaction with the ligand-bound receptor and an effector (in this case, adenylyl cyclase) that interacts with dissociated G-protein subunits to generate small molecule second messengers. AVP activates adenylyl cyclase, increasing the intracellular concentration of cAMP. The topology of adenylyl cyclase is characterized by two tandem repeats of six hydrophobic transmembrane domains separated by a large cytoplasmic loop and terminates in a large intracellular tail. The dimeric structure (C1 and C2) of the catalytic domains is represented. Conversion of adenosine triphosphate (ATP) to cAMP takes place at the dimer interface. Two aspartate residues (in C1) coordinate two metal co-factors (Mg2+ or Mn2+ represented here as two small black circles), which enable the catalytic function of the enzyme. Adenosine is shown as an open circle and the three phosphate groups (ATP) are shown as smaller open circles. PKA is the target of the generated cAMP. The binding of cAMP to the regulatory subunits of PKA induces a conformational change, causing these subunits to dissociate from the catalytic subunits. These activated subunits (C) as shown here are anchored to an aquaporin-2 (AQP2)-containing endocytic vesicle via an A-kinase-anchoring protein. The local concentration and distribution of the cAMP gradient are limited by phosphodiesterases (PDEs). Cytoplasmic vesicles carrying the water channels (represented as homotetrameric complexes) are fused to the luminal membrane in response to AVP, thereby increasing the water permeability of this membrane. The dissociation of the A-kinase-anchoring protein from the endocytic vesicle is not represented. Microtubules and actin filaments are necessary for vesicle movement toward the membrane. When AVP is not available, AQP2 water channels are retrieved by an endocytic process, and water permeability returns to its original low rate. Aquaporin-3 (AQP3) and aquaporin-4 (AQP4) water channels are expressed constitutively at the basolateral membrane.
Agre,
Aquaporin water channels (Nobel Lecture).
2004, Pubmed
Agre,
Aquaporin water channels (Nobel Lecture).
2004,
Pubmed
Arthus,
Report of 33 novel AVPR2 mutations and analysis of 117 families with X-linked nephrogenic diabetes insipidus.
2000,
Pubmed
Bettinelli,
Use of calcium excretion values to distinguish two forms of primary renal tubular hypokalemic alkalosis: Bartter and Gitelman syndromes.
1992,
Pubmed
Bichet,
X-linked nephrogenic diabetes insipidus: from the ship Hopewell to RFLP studies.
1992,
Pubmed
Bichet,
Epinephrine and dDAVP administration in patients with congenital nephrogenic diabetes insipidus. Evidence for a pre-cyclic AMP V2 receptor defective mechanism.
1989,
Pubmed
Bichet,
Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus.
1988,
Pubmed
Bircan,
A case of aquaporin 2 R85X mutation in a boy with congenital nephrogenic diabetes insipidus.
2008,
Pubmed
Birkenhäger,
Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure.
2001,
Pubmed
Birnbaumer,
Molecular cloning of the receptor for human antidiuretic hormone.
1992,
Pubmed
Boccalandro,
Characterization of an aquaporin-2 water channel gene mutation causing partial nephrogenic diabetes insipidus in a Mexican family: evidence of increased frequency of the mutation in the town of origin.
2004,
Pubmed
Boone,
Physiology and pathophysiology of the vasopressin-regulated renal water reabsorption.
2008,
Pubmed
Brenner,
Normal response of factor VIII and von Willebrand factor to 1-deamino-8D-arginine vasopressin in nephrogenic diabetes insipidus.
1988,
Pubmed
Canfield,
Identification and characterization of aquaporin-2 water channel mutations causing nephrogenic diabetes insipidus with partial vasopressin response.
1997,
Pubmed
,
Xenbase
Carroll,
Novel mutations underlying nephrogenic diabetes insipidus in Arab families.
2006,
Pubmed
Cheong,
Six novel mutations in the vasopressin V2 receptor gene causing nephrogenic diabetes insipidus.
1997,
Pubmed
Deen,
Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine.
1994,
Pubmed
,
Xenbase
de Mattia,
A novel mechanism in recessive nephrogenic diabetes insipidus: wild-type aquaporin-2 rescues the apical membrane expression of intracellularly retained AQP2-P262L.
2004,
Pubmed
,
Xenbase
de Mattia,
Lack of arginine vasopressin-induced phosphorylation of aquaporin-2 mutant AQP2-R254L explains dominant nephrogenic diabetes insipidus.
2005,
Pubmed
Earley,
THE MECHANISM OF ANTIDIURESIS ASSOCIATED WITH THE ADMINISTRATION OF HYDROCHLOROTHIAZIDE TO PATIENTS WITH VASOPRESSIN-RESISTANT DIABETES INSIPIDUS.
1962,
Pubmed
Estévez,
Barttin is a Cl- channel beta-subunit crucial for renal Cl- reabsorption and inner ear K+ secretion.
2001,
Pubmed
,
Xenbase
Fushimi,
Cloning and expression of apical membrane water channel of rat kidney collecting tubule.
1993,
Pubmed
,
Xenbase
Goji,
Novel mutations in aquaporin-2 gene in female siblings with nephrogenic diabetes insipidus: evidence of disrupted water channel function.
1998,
Pubmed
,
Xenbase
Green,
Charting a course for genomic medicine from base pairs to bedside.
2011,
Pubmed
Guyon,
Characterization of D150E and G196D aquaporin-2 mutations responsible for nephrogenic diabetes insipidus: importance of a mild phenotype.
2009,
Pubmed
,
Xenbase
Hochberg,
Autosomal recessive nephrogenic diabetes insipidus caused by an aquaporin-2 mutation.
1997,
Pubmed
Iolascon,
Characterization of two novel missense mutations in the AQP2 gene causing nephrogenic diabetes insipidus.
2007,
Pubmed
Jeck,
Hypokalemic salt-losing tubulopathy with chronic renal failure and sensorineural deafness.
2001,
Pubmed
Kamsteeg,
Importance of aquaporin-2 expression levels in genotype -phenotype studies in nephrogenic diabetes insipidus.
2000,
Pubmed
,
Xenbase
Kamsteeg,
Repulsion between Lys258 and upstream arginines explains the missorting of the AQP2 mutant p.Glu258Lys in nephrogenic diabetes insipidus.
2009,
Pubmed
Kamsteeg,
An impaired routing of wild-type aquaporin-2 after tetramerization with an aquaporin-2 mutant explains dominant nephrogenic diabetes insipidus.
1999,
Pubmed
,
Xenbase
Kamsteeg,
Reversed polarized delivery of an aquaporin-2 mutant causes dominant nephrogenic diabetes insipidus.
2003,
Pubmed
,
Xenbase
Knoers,
A variant of nephrogenic diabetes insipidus: V2 receptor abnormality restricted to the kidney.
1991,
Pubmed
Kuwahara,
Aquaporin-2, a vasopressin-sensitive water channel, and nephrogenic diabetes insipidus.
1998,
Pubmed
,
Xenbase
Kuwahara,
Three families with autosomal dominant nephrogenic diabetes insipidus caused by aquaporin-2 mutations in the C-terminus.
2001,
Pubmed
,
Xenbase
Langley,
Autosomal recessive inheritance of vasopressin-resistant diabetes insipidus.
1991,
Pubmed
Leduc-Nadeau,
New autosomal recessive mutations in aquaporin-2 causing nephrogenic diabetes insipidus through deficient targeting display normal expression in Xenopus oocytes.
2010,
Pubmed
,
Xenbase
Lin,
Two novel aquaporin-2 mutations responsible for congenital nephrogenic diabetes insipidus in Chinese families.
2002,
Pubmed
,
Xenbase
Loonen,
Aquaporin 2 mutations in nephrogenic diabetes insipidus.
2008,
Pubmed
Marr,
Cell-biologic and functional analyses of five new Aquaporin-2 missense mutations that cause recessive nephrogenic diabetes insipidus.
2002,
Pubmed
,
Xenbase
Marr,
Heteroligomerization of an Aquaporin-2 mutant with wild-type Aquaporin-2 and their misrouting to late endosomes/lysosomes explains dominant nephrogenic diabetes insipidus.
2002,
Pubmed
Moon,
Novel mutation of aquaporin-2 gene in a patient with congenital nephrogenic diabetes insipidus.
2009,
Pubmed
Morishita,
Nephrogenic diabetes insipidus in mice lacking all nitric oxide synthase isoforms.
2005,
Pubmed
Mulders,
An aquaporin-2 water channel mutant which causes autosomal dominant nephrogenic diabetes insipidus is retained in the Golgi complex.
1998,
Pubmed
,
Xenbase
Mulders,
New mutations in the AQP2 gene in nephrogenic diabetes insipidus resulting in functional but misrouted water channels.
1997,
Pubmed
,
Xenbase
Müller,
Desmopressin for nocturnal enuresis in nephrogenic diabetes insipidus.
2002,
Pubmed
Murata,
Structural determinants of water permeation through aquaporin-1.
2000,
Pubmed
Nedvetsky,
Regulation of aquaporin-2 trafficking.
2009,
Pubmed
Nielsen,
Aquaporins in the kidney: from molecules to medicine.
2002,
Pubmed
Ohzeki,
Familial cases of congenital nephrogenic diabetes insipidus type II: Remarkable increment of urinary adenosine 3',5'-monophosphate in response to antidiuretic hormone.
1984,
Pubmed
Oksche,
Two novel mutations in the aquaporin-2 and the vasopressin V2 receptor genes in patients with congenital nephrogenic diabetes insipidus.
1996,
Pubmed
Olesen,
Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus.
2011,
Pubmed
Peters,
Clinical presentation of genetically defined patients with hypokalemic salt-losing tubulopathies.
2002,
Pubmed
Ragnarsson,
The Nobel trail of Vincent du Vigneaud.
2007,
Pubmed
Raju,
The Nobel chronicles. 1994: Alfred G Gilman (b 1941) and Martin Rodbell (1925-98).
2000,
Pubmed
Raju,
The Nobel chronicles. 1971: Earl Wilbur Sutherland, Jr. (1915-74).
1999,
Pubmed
Rehmann,
Capturing cyclic nucleotides in action: snapshots from crystallographic studies.
2007,
Pubmed
Ring,
WNK4 regulates activity of the epithelial Na+ channel in vitro and in vivo.
2007,
Pubmed
,
Xenbase
Rosenthal,
Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus.
1992,
Pubmed
Sahakitrungruang,
Identification of two novel aquaporin-2 mutations in a Thai girl with congenital nephrogenic diabetes insipidus.
2008,
Pubmed
Savelkoul,
p.R254Q mutation in the aquaporin-2 water channel causing dominant nephrogenic diabetes insipidus is due to a lack of arginine vasopressin-induced phosphorylation.
2009,
Pubmed
Seibold,
Structure and chromosomal localization of the human antidiuretic hormone receptor gene.
1992,
Pubmed
Sohara,
Pathogenesis and treatment of autosomal-dominant nephrogenic diabetes insipidus caused by an aquaporin 2 mutation.
2006,
Pubmed
Tajkhorshid,
Control of the selectivity of the aquaporin water channel family by global orientational tuning.
2002,
Pubmed
van Lieburg,
Patients with autosomal nephrogenic diabetes insipidus homozygous for mutations in the aquaporin 2 water-channel gene.
1994,
Pubmed
,
Xenbase
Vargas-Poussou,
Mutations in the vasopressin V2 receptor and aquaporin-2 genes in 12 families with congenital nephrogenic diabetes insipidus.
1997,
Pubmed
Waldegger,
Barttin increases surface expression and changes current properties of ClC-K channels.
2002,
Pubmed
,
Xenbase
Zaki,
Nephrogenic diabetes insipidus, thiazide treatment and renal cell carcinoma.
2006,
Pubmed